See more : Auto Server Co., Ltd. (5589.T) Income Statement Analysis – Financial Results
Complete financial analysis of TC Biopharm (Holdings) Plc (TCBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TC Biopharm (Holdings) Plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- NEXTAGE Co., Ltd. (3186.T) Income Statement Analysis – Financial Results
- Round One Corporation (RNDOF) Income Statement Analysis – Financial Results
- Johnson Electric Holdings Limited (0179.HK) Income Statement Analysis – Financial Results
- PRO DV AG (PDA.DE) Income Statement Analysis – Financial Results
- Danske Invest Fonde (DKIFO.CO) Income Statement Analysis – Financial Results
TC Biopharm (Holdings) Plc (TCBP)
About TC Biopharm (Holdings) Plc
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 3.84M | 1.98M | 1.98M | 3.43M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 3.84M | 1.98M | 1.98M | 3.43M |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 7.77M | 7.59M | 6.16M | 6.68M | 8.61M |
| General & Administrative | 6.47M | 8.34M | 3.11M | 2.21M | 3.01M |
| Selling & Marketing | 402.31K | 402.31K | 0.00 | 0.00 | 0.00 |
| SG&A | 6.87M | 8.74M | 3.11M | 2.21M | 3.01M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.91M | 124.90K | 13.52M | 8.32M | 10.07M |
| Cost & Expenses | 6.91M | 124.90K | 13.52M | 8.32M | 10.07M |
| Interest Income | 83.03K | 6.75M | 3.44M | 291.03K | 253.51K |
| Interest Expense | 0.00 | 6.75M | 3.44M | 292.06K | 275.41K |
| Depreciation & Amortization | 630.06K | 762.47K | 811.96K | 878.64K | 721.93K |
| EBITDA | -13.61M | -11.32M | -6.48M | -5.26M | -5.92M |
| EBITDA Ratio | 0.00% | -294.48% | -327.25% | -303.65% | -172.71% |
| Operating Income | -14.24M | -12.08M | -7.29M | -6.89M | -6.64M |
| Operating Income Ratio | 0.00% | -314.32% | -368.28% | -348.05% | -193.78% |
| Total Other Income/Expenses | 7.24M | 9.05M | -7.70M | -291.03K | -253.51K |
| Income Before Tax | -7.00M | -3.03M | -14.98M | -6.63M | -6.89M |
| Income Before Tax Ratio | 0.00% | -78.91% | -757.25% | -335.07% | -201.18% |
| Income Tax Expense | -1.09M | 1.72M | 1.41M | 1.17M | 826.07K |
| Net Income | -5.91M | -1.31M | -13.58M | -5.46M | -6.07M |
| Net Income Ratio | 0.00% | -34.17% | -686.12% | -275.84% | -177.07% |
| EPS | -191.21 | -382.31 | -6.95K | -2.88K | 0.00 |
| EPS Diluted | -191.21 | -382.31 | -6.95K | -2.88K | 0.00 |
| Weighted Avg Shares Out | 30.89K | 3.44K | 1.95K | 1.89K | 1.89K |
| Weighted Avg Shares Out (Dil) | 30.89K | 3.44K | 1.95K | 1.89K | 1.89K |
TC BioPharm Announces Pricing of $3.5 Million Public Offering
EDINBURGH, Scotland , Dec. 19, 2023 /PRNewswire/ -- TC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the pricing of a public offering of...
TC BioPharm Announces Formation of Commercial Development Division, Led by Industry Veteran, Dr. Lauren Bor Ph.D
EDINBURGH, Scotland , Dec. 18, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that the creation of a new...
TC BioPharm Announces Plan to Implement ADS Ratio Change
EDINBURGH, Scotland , Dec. 13, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that it will change its ratio...
TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug
The FDA clears TC BioPharm's (TCBP) investigational new drug application seeking approval to begin a clinical study on its pipeline candidate, TCB008, for treating acute myeloid leukemia. Stock declines.
TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia
EDINBURGH, Scotland , Nov. 27, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that the FDA provides clearance on...
TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results
No Significant Safety Concerns Observed in Safety Cohort Management expects to expand ACHIEVE trial in Q1 EDINBURGH, Scotland , Nov. 14, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing...
TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials
Creates economic leverage with vertical integration of database and management EDINBURGH, Scotland , Nov. 2, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies...
TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements
Excellos to provide scale up solution for final manufacturing in TCBP facility EDINBURGH, Scotland , Oct. 25, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T...
TC BioPharm Announces Submission of Investigational New Drug (IND) Application to U.S. FDA for Treatment of Relapse/Refractory AML
Filing is supported by strong clinical data and IND enabling pre-clinical data associated withTCB-008 in treatment of Acute Myeloid Leukemia EDINBURGH, Scotland , Oct. 23, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage...
TC BioPharm to Present at the LD Micro Main Event XVI
EDINBURGH, Scotland , Sept. 27, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that CEO, Bryan Kobel will present...
Source: https://incomestatements.info
Category: Stock Reports